The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...

An analysis from the Congressional Budget Office warns that cuts to the National Institutes of Health and FDA drug reviews could significantly reduce the number of new medications reaching the U.S.

Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast ...